

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IDO2 in direct ELISAs.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 1001802
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Synthetic peptide containing human IDO2 Met1-Val407 Accession # Q6ZQW0
<b>Conjugate</b>	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
<b>Formulation</b>	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

**Immunohistochemistry** Optimal dilution of this antibody should be experimentally determined.

## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

## BACKGROUND

Indoleamine 2,3-dioxygenase (IDO2) is a 47 kDa heme-containing cytosolic dioxygenase. Human IDO2 shares 64% aa sequence identity with mouse IDO2. IDO2 is one of three dioxygenases capable of catalyzing the first and rate-limiting step of the L-kynurenine pathway (KP): oxidative cleavage of the essential amino acid L-tryptophan to form N formyl kynurenine (1). Of these proteins, IDO1 and IDO2 are both related, monomeric enzymes but share only 38% aa sequence identity. The IDO isoforms are not functionally redundant. Although expression of IDO2 has been upregulated in some cancers (2,3), IDO2 expression is generally restricted to the liver, kidney, brain, and certain immune cell types unlike the more ubiquitously expressed indoleamine 2,3-dioxygenase (IDO) (1). Differential inhibition of IDO1 and IDO2 is observed with several molecules (4,5). IDO2 has significantly lower tryptophan catabolic activity than IDO1 and IDO2 (4, 6-8) suggesting it does not play a significant physiological role in the KP. Instead, IDO2 may have an alternative functional role: either non-enzymatic or utilizing a more physiologically relevant substrate (5,7). IDO2 function operates as a pro-inflammatory mediator in autoimmune inflammatory disorders (8, 9-11). It is a candidate for co-therapeutic targeting for treatment in these diseases (10-11).

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.